Eli Lilly (LLY)

874.90
-9.06 (-1.03%)
NYSE · Last Trade: Apr 27th, 3:40 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close883.96
Open878.13
Bid874.85
Ask874.94
Day's Range872.20 - 891.20
52 Week Range623.78 - 1,133.95
Volume1,551,919
Market Cap836.91B
PE Ratio (TTM)38.12
EPS (TTM)22.9
Dividend & Yield6.920 (0.79%)
1 Month Average Volume2,950,662

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The CRDL lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
Via Get News · April 27, 2026
Is Bristol Myers Squibb the Best Bargain in Big Pharma?fool.com
This pharma stock is cheap for a reason.
Via The Motley Fool · April 27, 2026
Is SpaceX Really Worth $1.75 Trillion -- or Is That Actually Too Low?fool.com
This space stock could literally go "to the moon."
Via The Motley Fool · April 27, 2026
Nuclear Is Back in a Big Way. Here Are 2 Stocks to Consider.fool.com
With more focus on nuclear energy, companies connected to nuclear power could be strong long-term investments.
Via The Motley Fool · April 26, 2026
This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Streetfool.com
Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full.
Via The Motley Fool · April 26, 2026
Should You Add a Healthcare Stock to Your Portfolio This Month? And Should It Be Eli Lilly (LLY)?fool.com
Eli Lilly is a giant in the weight-loss drug realm, and it's aiming to grow more.
Via The Motley Fool · April 25, 2026
Looking to Buy the Tech Turnaround? This Low-Cost Vanguard ETF Might Be Your Best Entry Point.fool.com
You get the upside of the sector, while minimizing some of the risks.
Via The Motley Fool · April 25, 2026
Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom?fool.com
The weight loss drug market may reach almost $100 billion in a few years.
Via The Motley Fool · April 25, 2026
Why Eli Lilly Stock Flopped on Fridayfool.com
High hopes for a freshly approved drug might not be realized, if early data is any indication.
Via The Motley Fool · April 24, 2026
Why Eli Lilly (LLY) Shares Are Trading Lower Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.6% in the afternoon session after disappointing weekly prescription number...
Via StockStory · April 24, 2026
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Via Chartmill · April 24, 2026
Deal Dispatch: QXO Nabs TopBuild For $17 Million, Voya Financial Urged To Evaluate Strategic Options, Pat McGrath Exits Chapter 11benzinga.com
Major M&A deals this week include Eli Lilly buys Kelonia for $7 billion, Honeywell sells PSS to Brady Corp., KSL buys Invited Clubs.
Via Benzinga · April 24, 2026
These S&P500 stocks are gapping in today's sessionchartmill.com
Via Chartmill · April 24, 2026
Expert Matchmaker in Indianapolis Report by CX Research Institute
Indianapolis, IN - CX Research Institute announced today the publication of its comprehensive research report evaluating the best expert matchmakers in the Indianapolis metropolitan area. VIDA Select earned the top ranking with a score of 92 out of 100 points, leading eight other prominent matchmaking and dating services in a rigorous comparative analysis.
Via AB Newswire · April 24, 2026
Battle Of The Weight-Loss Pills Continues With A Shocking Twistinvestors.com
Eli Lilly stock skidded early Friday as Novo Nordisk's oral Wegovy continued to outpace Lilly's new obesity pill, Foundayo.
Via Investor's Business Daily · April 24, 2026
This Vanguard Index Fund Could Turn $500 Per Month Into a $1.4 Million Portfolio as the AI Boom Unfoldsfool.com
Young adults with median earnings can build sizable portfolios by retirement by regularly purchasing shares of the Vanguard S&P 500 Growth ETF.
Via The Motley Fool · April 24, 2026
Q4 Earnings Roundup: Merck (NYSE:MRK) And The Rest Of The Branded Pharmaceuticals Segment
Let’s dig into the relative performance of Merck (NYSE:MRK) and its peers as we unravel the now-completed Q4 branded pharmaceuticals earnings season. Looking...
Via StockStory · April 23, 2026
Why Vista Just Opened a $3 Million Position in Federated Hermesfool.com
Federated Hermes delivers asset management solutions across equity, fixed income, and money market funds to a diverse client base.
Via The Motley Fool · April 23, 2026
Amazon Aims to Take Over the GLP-1 Market Next. Will That Move the Needle for AMZN Stock?
Amazon is expanding into integrated weight-loss care with a scalable healthcare model. Can this expansion meaningfully drive AMZN stock upside?
Via Barchart.com · April 23, 2026
Positive Results on MAVERIC Phase III Trial and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The CRDL lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.
Via Get News · April 23, 2026
Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?fool.com
Novo Nordisk stock has been stuck in a downward spiral for quite some time.
Via The Motley Fool · April 23, 2026
Hims & Hers Jumps On Its New Eli Lilly-Tied Approach To Obesityinvestors.com
Hims & Hers Health can now connect its customers with self-pay prices for Eli Lilly's weight-loss drugs.
Via Investor's Business Daily · April 23, 2026
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Winsfool.com
Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.
Via The Motley Fool · April 23, 2026
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met
By Equity Insider · Via GlobeNewswire · April 23, 2026
3 Healthcare Stocks With the Most Durable Competitive Moatsfool.com
These companies offer a clear path to sustained earnings growth.
Via The Motley Fool · April 23, 2026